Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AbbVie Inc.
Report date February 28, 2025 · Filed March 04, 2025
Section 16 reporting ended · disclosed 2025-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 7,797 |
Reported balance
After 2025-02-28 transaction · row 1
1 source rowRow 1 · 2025-02-28 · Tax withholding · Disposed 3,699 · Balance 7,797 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2025 Filed Mar 4, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 3,699 | $205.02 | $758,368.98 |
DisclosureSEC source: 0001415889-25-006586 · form4-03042025_050321.xml · nonDerivative · entry 1 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,797 Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 6,522 | $105.92 Strike: $105.92 | $690,810.24 |
DisclosureSEC source: 0001415889-25-006025 · form4-02282025_050204.xml · derivative · entry 6 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,794 Underlying: Common Stock · 6,522 shares Expires 2031-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 9,738 | $93.50 Strike: $93.50 | $910,503.00 |
DisclosureSEC source: 0001415889-25-006025 · form4-02282025_050204.xml · derivative · entry 5 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,373 Underlying: Common Stock · 9,738 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 16,260 | $203.41 | $3,307,446.60 |
DisclosureSEC source: 0001415889-25-006025 · form4-02282025_050204.xml · nonDerivative · entry 4 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,496 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.39 to $203.48, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: The reporting person transferred 1,150 shares of common stock to his former spouse pursuant to a domestic relations order since his last ownership report and has ceased to be the beneficial owner of such shares. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 6,522 | $105.92 | $690,810.24 |
DisclosureSEC source: 0001415889-25-006025 · form4-02282025_050204.xml · nonDerivative · entry 3 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 9,738 | $93.50 | $910,503.00 |
DisclosureSEC source: 0001415889-25-006025 · form4-02282025_050204.xml · nonDerivative · entry 2 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,684 | $203.40 | $545,925.60 |
DisclosureSEC source: 0001415889-25-006025 · form4-02282025_050204.xml · nonDerivative · entry 1 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,646 Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 6,250 | $0.00 Strike: $192.86 | $0.00 |
DisclosureSEC source: 0001415889-25-004464 · form4-02182025_050220.xml · derivative · entry 5 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2035-02-12 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,084 on February 13, 2026, 2,083 on February 13, 2027, and 2,083 on February 13, 2028. F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,084 on February 13, 2026, 2,083 on February 13, 2027, and 2,083 on February 13, 2028. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004464 · form4-02182025_050220.xml · nonDerivative · entry 4 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,330 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004464 · form4-02182025_050220.xml · nonDerivative · entry 3 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,656 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004464 · form4-02182025_050220.xml · nonDerivative · entry 2 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,052 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 3,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004464 · form4-02182025_050220.xml · nonDerivative · entry 1 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,578 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 1,800 | $93.50 Strike: $93.50 | $168,300.00 |
DisclosureSEC source: 0001415889-24-029754 · form4-12182024_051202.xml · derivative · entry 3 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,111 Underlying: Common Stock · 1,800 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 1,800 | $172.24 | $310,032.00 |
DisclosureSEC source: 0001415889-24-029754 · form4-12182024_051202.xml · nonDerivative · entry 2 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,983 Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 17:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 1,800 | $93.50 | $168,300.00 |
DisclosureSEC source: 0001415889-24-029754 · form4-12182024_051202.xml · nonDerivative · entry 1 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 17:50 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 5,144 | $176.65 | $908,687.60 |
DisclosureSEC source: 0001415889-24-006164 · form4-03012024_050323.xml · nonDerivative · entry 2 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,983 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.65 to $176.68, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: The reporting person transferred 1,745 shares of common stock to his former spouse pursuant to a domestic relations order since his last ownership report and has ceased to be the beneficial owner of such shares. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 17:50 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 5,339 | $178.99 | $955,627.61 |
DisclosureSEC source: 0001415889-24-006164 · form4-03012024_050323.xml · nonDerivative · entry 1 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,872 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 6,934 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004422 · form4-02202024_050245.xml · derivative · entry 5 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,934 Underlying: Common Stock · 6,934 shares Expires 2034-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,312 on February 15, 2025, 2,311 on February 15, 2026, and 2,311 on February 15, 2027. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004422 · form4-02202024_050245.xml · nonDerivative · entry 4 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,211 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004422 · form4-02202024_050245.xml · nonDerivative · entry 3 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,607 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004422 · form4-02202024_050245.xml · nonDerivative · entry 2 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,131 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 17:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004422 · form4-02202024_050245.xml · nonDerivative · entry 1 Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,243 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.